Eli Lilly's Obesity Drug Woes Fuel Novo Nordisk's 7.45% Surge as $1.99B Volume Ranks 42nd in Daily Trading

On August 7, 2025, Novo Nordisk (NVO) shares rose 7.45% with a trading volume of $1.99 billion, ranking 42nd in daily market activity. The stock’s performance was driven by underwhelming clinical results for Eli Lilly’s oral obesity drug orforglipron, which raised concerns over its efficacy and tolerability. Analysts noted that Lilly’s trial data, showing a 11.5% placebo-adjusted weight loss over 72 weeks, fell short of investor expectations of 13–15%, while high discontinuation rates—particularly 24.4% for the highest dose—further dampened confidence in the drug’s long-term viability.

Market participants shifted their focus to Novo Nordisk’s oral semaglutide, which remains a key player in the GLP-1 obesity drug space. Analysts at Mizuho and Wolfe Research highlighted that Lilly’s results could narrow the competitive gap between the two firms, though they emphasized unresolved challenges in tolerability for orforglipron. Despite these concerns, some experts acknowledged the drug’s potential as a consumer-friendly option, albeit with near-term hurdles. Novo’s recent sales outlook revision for 2025 had previously pressured its stock, but the latest developments appear to have restored investor confidence in its market leadership.

The strategy of purchasing the top 500 stocks by daily trading volume and holding them for one day delivered a 166.71% return from 2022 to the present, outperforming the benchmark return of 29.18% by 137.53%. This underscores the role of liquidity concentration in short-term stock performance, particularly in volatile markets. The outperformance highlights how high-volume stocks can capitalize on macroeconomic shifts and investor behavior, offering significant returns despite inherent risks.